OMB No. 0925-0001 and 0925-0002 (Rev. 09/17 Approved Through 03/31/2020)

BIOGRAPHICAL SKETCH

Provide the following information for the Senior/key personnel and other significant contributors.
Follow this format for each person. **DO NOT EXCEED FIVE PAGES.**

NAME: Korte, Jeffrey Edwerth

eRA COMMONS USER NAME (credential, e.g., agency login): kortej

POSITION TITLE: Associate Professor

EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable. Add/delete rows as necessary.)

| INSTITUTION AND LOCATION | DEGREE(if applicable) | Completion DateMM/YYYY | FIELD OF STUDY |
| --- | --- | --- | --- |
| Rice University, Houston, Texas | BA | 05/1992 | Psychology |
| University of North Carolina at Chapel Hill | MSPH | 05/1997 | Epidemiology |
| University of North Carolina at Chapel Hill | PhD | 12/1999 | Epidemiology |
| International Agency for Research on Cancer, |  | 01/2001 | Environmental Cancer |
|  Lyon, France |  |  |  Epidemiology |

**A. Personal Statement**

As an epidemiologist at Medical University of South Carolina, I have developed a portfolio of independent and collaborative research with clinicians and scientists from across the campus and elsewhere. Having published over 50 peer-reviewed papers to date, I have significant experience with clinical research as well as population-based research in epidemiology. My primary focus is in infectious disease epidemiology with a particular focus on HIV. I also collaborate with researchers around MUSC and elsewhere in the areas of substance use disorders and women’s health. I serve as the Graduate Training Director for Epidemiology in our department and teach the second-semester core epidemiology methods class for our PhD, MS, and MPH programs.

**B. Positions and Honors
Primary Positions and Employment**

**1992-1994 Research Assistant, North Carolina State University**

**1994-1999 Research Assistant, Department of Epidemiology, University of North Carolina at Chapel Hill**

**1995 Teaching Assistant, Department of Epidemiology, University of North Carolina at Chapel Hill**

**1999-2001 In-house Postdoctoral Fellow, International Agency for Research on Cancer, Lyon, France**

**2001-2006 Assistant Professor/Research, Department of Obstetrics and Gynecology, University of Texas Health Science Center at San Antonio**

**2006-2015 Assistant Professor, Department of Public Health Sciences, Medical University of South Carolina, Charleston, South Carolina (formerly known as Department of Biostatistics, Bioinformatics, and Epidemiology [2006-2009] and formerly known as Department of Medicine, Division of Biostatistics and Epidemiology [2009-2012])**

**2016-present Associate Professor, Department of Public Health Sciences, Medical University of South Carolina, Charleston, South Carolina**

**Secondary Positions**

**2001-2006 Full Member, Center for Epidemiology and Biostatistics, University of Texas Health Science Center at San Antonio**

**2002-2006 Interdisciplinary Member, Center for Community-Based Health Promotion in Women and Children, University of Texas Health Science Center at San Antonio**

**2005-2006 Associate Faculty, UTHSCSA National Center of Excellence in Women’s Health, University of Texas Health Science Center at San Antonio**

**2006-2007 Associate Member, Graduate Faculty, Medical University of South Carolina, Charleston, South Carolina**

**2006-present Research Member, Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina**

**2007-present Full Member, Graduate Faculty, Medical University of South Carolina, Charleston, South Carolina**

**2009-2012 Co-Director, Research Core, Center for Community Health Partnerships, Medical University of South Carolina, Charleston, South Carolina**

**2012-2015 Board Member, Academic Advisory Board, Community Engagement Core, South Carolina Clinical and Translational Research Institute, MUSC, Charleston, South Carolina**

**2017-present Graduate Training Director, Division of Epidemiology, Department of Public Health Sciences, MUSC, Charleston, South Carolina**

**Other Experience and Professional Memberships**

**2006-2008 Member of Communications Committee, American College of Epidemiology**

**2008-2012 Subgroup leader: Policy and Advocacy Subgroup, Moving to Action committee for prevention of cervical cancer, South Carolina Cancer Alliance**

**1999-2001 Special Training Award from the International Agency for Research on Cancer, World Health Organization: In-House Postdoctoral Fellowship, Lyon, France**

**2008-present Reviewer for NIAID special emphasis panels**

**2010-present Reviewer for CDC special emphasis panels**

**2009-present Reviewer for MUSC Community Engaged Scholar grant program**

**2015 Reviewer for MUSC Center for Global Health pilot project grant program**

**Honors**

**1987 National Honor Society**

**1988-1992 National Merit Scholarship, Rice University**

**1999 Overall Student Merit Award, Society for Risk Analysis**

**1999 Student Merit Award in Dose-Response Assessment, Dose-Response Specialty Group of the Society for Risk Analysis**

**C. Contributions to Science**

1. In my career thus far I have focused mainly on different aspects of risky behavior, including risky sexual behavior and substance use. In addition, my work has been characterized by an overarching focus on women’s health. During graduate school and postdoctoral fellowship, though, I also developed experience in environmental cancer epidemiology, contributing to our understanding of tobacco carcinogens. This early work also extends to a 2014 publication.

1. **Korte JE**, Hertz-Picciotto I, Schulz MR, Ball LM, Duell EJ. The contribution of benzene to smoking-induced leukemia. Environmental Health Perspectives 108(4):333-339, 2000.
2. **Korte JE**, Brennan P, Henley SJ, Boffetta P. Dose-specific meta-analysis and sensitivity analysis of alcohol consumption and lung cancer risk. American Journal of Epidemiology 155(6):496-506, 2002.
3. Alberg AJ, **Korte JE**. Invited commentary: parental smoking as a risk factor for adult tobacco use: Can maternal smoking during pregnancy be distinguished from the social environmental influence during childhood? Am J Epidemiol. 2014 Jun 15;179(12):1418-21. PMCID: PMC4051876.

2. Focusing on behavioral prevention of sexually transmitted infections, I helped to ascertain the efficacy of behavioral interventions in high-risk women and couples to prevent STI. This work included extensive development of behavioral questionnaire measures, the study of symptoms and laboratory detection in relation to a novel and under-studied infection (*Mycoplasma genitalium*), and study of sociodemographic, clinical, and behavioral predictors of infection and prevention efficacy.

1. **Korte JE**, Shain RN, Holden AEC, Piper JM, Perdue ST, Champion JD, Sterneckert K. Reduction in sexual risk behaviors and infection rates among African Americans and Mexican Americans. Sexually Transmitted Diseases 31(3):166-73, 2004.
2. Piper JM, **Korte JE**, Holden AEC, Shain RN, Perdue S, Champion JD, Newton ER. Development of composite symptom variables for quantitative analysis of genitourinary symptomatology in women. International Journal of STD and AIDS 16(2):128-32, 2005.
3. **Korte JE**, Baseman JB, Cagle MP, Herrera C, Piper JM, Holden AE, Perdue ST, Champion JD, Shain RN. Cervicitis and genitourinary symptoms in women culture positive for *Mycoplasma genitalium*. American Journal of Reproductive Immunology 55(4):265-75, 2006.
4. Holden AEC, Shain RN, Miller WB, Piper JM, Perdue ST, Thurman AR, **Korte JE**. The influence of depression on sexual risk reduction and STD infection in a controlled, randomized intervention trial. Sexually Transmitted Diseases 35(10):898-904, 2008.

3. At the intersection of cancer and infectious disease, I have developed a focus on human papillomavirus, including the study of barriers to vaccination and cofactors for HPV infection and persistence.

a. Young-Pierce J, **Korte JE**, Carr LA, Gasper CB, Modesitt SC. Post approval human papillomavirus vaccine uptake is higher in minorities compared to whites in girls presenting for well-child care. In press, Vaccines.

b. Sundstrom B, Carr LA, DeMaria AL, **Korte JE**, Modesitt SC, Young Pierce JL. Protecting the next generation: elaborating the health belief model to increase HPV vaccination among college-age women. In press, Social Marketing Quarterly.

c. Lazenby GB, Taylor PT, Badman BS, Mchaki E, **Korte JE**, Soper DE, Young Pierce J. An Association between *Trichomonas vaginalis* and high-risk human papillomavirus in rural Tanzanian women undergoing cervical cancer screening. Clinical Therapeutics 2014 Jan;36(1):38-45.

4. In the area of substance use disorders, I have conducted methodological work on outcome definitions and appropriate analytic techniques. In addition, I have identified subgroups who are more likely to be retained in care and to have effective treatment outcomes.

1. **Korte JE**, Rosa CL, Wakim PG, Perl HI. Addiction treatment trials: how gender, race/ethnicity, and age relate to ongoing participation and retention in clinical trials. Substance Abuse and Rehabilitation 2011 Nov 22;2:205-18. Epub 2011 Nov 10. PMCID: PMC3846502.
2. **Korte JE**, Magruder KM, Chiuzan CC, Logan SL, Killeen T, Bandyopadhyay D, Brady KT. Assessing drug use during follow-up: direct comparison of candidate outcome definitions in pooled analyses of addiction treatment studies. Am J Drug Alcohol Abuse. 2011 Sep;37(5):358-66. NIHMSID #308698.
3. **Korte JE**, Hiott FB, Brady KT, Malcolm RJ, See RE. Distinctive characteristics of methamphetamine users presenting at public clinics: Steep rise in South Carolina, United States, 2000-2005. Drug Alcohol Depend 2011 May 1;115(1-2):9-15. Epub 2010 Dec 9.
4. Prisciandaro JJ, **Korte JE**, McRae-Clark AL, Brady KT. Associations between behavioral disinhibition and cocaine use history in individuals with cocaine dependency. Addictive Behaviors, October 2012, 37(10):1185-88.

5. In recent years I have worked to translate my experience into a research program on HIV. This effort has paid off with several new grants on HIV self-testing, and HIV care integration in Africa. These ongoing studies are an outgrowth of my previous work in women’s health, sexually transmitted infections, and high-risk behavior in general. A selection of my published work relevant to HIV includes a new review article on HIV selof-testing, a study of rapid HIV testing in the context of substance abuse treatment clinics, and predictors of risky sexual behavior.

1. Stevens DR, Vrana CJ, Dlin RE, **Korte JE**. A Global Review of HIV Self-testing: Themes and Implications. AIDS Behav. doi: 10.1007/s10461-017-1707-8. Epub 2017 Feb 02.
2. Haynes LF, **Korte JE**, Holmes BE, Gooden L, Matheson T, Feaster DJ, Leff JA, Wilson L, Metsch LR, Schackman BR. HIV rapid testing in substance abuse treatment: Implementation following a clinical trial. Eval Program Plann 2011 Nov;34(4):399-406. doi: 10.1016/j.evalprogplan.2011.02.007. Epub 2011 Mar 1.
3. Merghati-Khoei E, Rimaz S, **Korte JE**, Back SE, Brady KT, Abad M, Shamsalizadeh N. Intimate partner violence and risky sexual behaviors among Iranian women with substance use disorders. Medical Journal of the Islamic Republic of Iran (Med J Islam Repub Iran) (7 February) 29:174, 2015.
4. Champion JD, Piper JM, Holden AE, Shain RN, **Korte JE**. Relationship of abuse and pelvic inflammatory disease risk behavior in minority adolescents. Journal of the American Academy of Nurse Practitioners 17(6):234-41, 2005.

**Complete List of Published Work:**

<http://www.ncbi.nlm.nih.gov/sites/myncbi/jeffrey.korte.1/bibliography/41150736/public/?sort=date&direction=ascending>

**D. Additional Information: Research Support and/or Scholastic Performance**

**Active**

7R01AI129411-02 (Dorman) 02/01/17 – 01/31/21

NIH/NIAID

*“Accuracy of the Xpert Ultra for diagnosis of pulmonary tuberculosis”*

The aims of this project are 1) to determine the clinical diagnostic accuracy of the Ultra test for detection of M. tuberculosis in sputum; 2) to refine estimates of Ultra specificity for detection of rifampin resistance; and 3) to characterize short-term participant outcomes including initiation of treatment and to model the potential health impact and cost-effectiveness of TB diagnosis using Ultra. Study results are expected to inform policy guidance disseminated by the WHO and other bodies.

 (Principal Investigator: Korte) 12/01/17 – 11/30/18

MUSC Center for Global Health

*“HIV oral self-testing in Tanzania”*

In this internally funded pilot project, we will recruit household members from two matched communities near Bagamoyo, Tanzania. In the control community, household members will be offered standard rapid blood-based HIV testing. In the intervention community, household members will be offered the additional option of HIV oral self-testing, including leaving kits at the home. All participants will be followed for outcomes including testing uptake and linkage to care.

 (Principal Investigator: Korte) 01/19/16 – 10/31/18

Bill and Melinda Gates Foundation; via International Initiative for Impact Evaluation (3ie)

*“HIV self-testing for partners of women attending antenatal care in central Uganda: uptake and linkage to care post-test”*

In this project in collaboration with Makerere University in Kampala, we will randomize antenatal care patients to two arms: standard of care, or standard of care plus provision of oral HIV self-testing kits. The primary outcome of the study is HIV testing rates among the male partners, with the goal of measuring the impact of self-testing kit provision. The study will be implemented in three high-volume clinical facilities around central Uganda.

UL1TR000062 (Brady) 07/01/09 – 03/31/19

NIH/NCATS

South Carolina Clinical and Translational Research Institute (SCTR)

SCTR is the catalyst for changing the culture of biomedical research, facilitating sharing of resources and expertise, and streamlining research-related processes to bring about large-scale change in the clinical and translational research efforts in South Carolina.

Role: Co-Investigator

U10 DA013727 (Brady/Carpenter) 09/30/00 – 08/31/20

NIH/NIDA

Southern Consortium Node of the Clinical Trials Network

As part of NIDA’s Clinical Trials Network, the South Carolina Consortium will attempt to bridge the gap between research and community based settings by developing an infrastructure to allow for the conduct of substance abuse psychological and pharmacological research trials.

Role: Co-investigator

5 R25 DA020537 (Back/Brady) 05/26/06 – 04/30/21

NIH/NIDA

Drug Abuse Research Training Program

The DART program is designed to attract, train, and advance physicians’ careers as independent investigators in patient-oriented drug abuse research.

Role: Co-Investigator

**Completed**

(Principal Investigator: Fedoroff/Dwyer) 07/01/16 – 06/30/17

American Academy of Psychiatry and the Law Institute for Education and Research (AIER)

Understanding Sexual Offenders and Substance Use: Implications of Specific Drug and Alcohol Use Before and During Offending.

The goal of this project was to identify the prevalence of substance use before and during sexual offenses, and examine specific types of substances and patterns of substance use related to specific subtypes of sexual offending (including hands-on versus hands-off offenses, and child versus adult victim).

Role: Co-investigator

(Principal Investigator: Korte) 06/01/16 – 05/30/17

MUSC Center for Global Health

*“Survey of HIV Testing at Nairobi VAP Football Tournaments”*

In this internally funded pilot project, we recruited low-income youth and young adults in Nairobi, Kenya, to ascertain knowledge, attitudes, and behavior around HIV testing, HIV self-testing, and sexual behaviors.

(Principal Investigator: Korte) 12/01/14 – 02/28/17

Bill and Melinda Gates Foundation; via International Initiative for Impact Evaluation (3ie)

*“Evaluation of Treatment Retention with Integration of HIV Services in Côte d’Ivoire”*

In this project in collaboration with Jhpiego, we built on an ongoing CDC-funded project in Côte d’Ivoire that is focused on integrating HIV care with other clinical services. In the new evaluation project, we studied the impact of this intervention on rates of retention on antiretroviral therapy among HIV-positive individuals.

(Principal Investigator: Korte) 11/01/14 – 03/31/16

Bill and Melinda Gates Foundation; via International Initiative for Impact Evaluation (3ie)

*“HIV Self-Testing Intervention Among Expectant Fathers in Kenya”*

In this individually randomized controlled trial in collaboration with Jhpiego, we randomized antenatal care patients to three arms: standard of care, standard of care plus improved information, and the intervention arm in which we provide HIV self-testing kits for the women to take home for their male partners. The primary outcome of the study is HIV testing rates among the male partners, with the goal of measuring the impact of self-testing kit provision. The study was implemented in fourteen high-volume clinical facilities around Kenya.

(Principal Investigator: Korte) 02/28/14 – 07/23/15

Bill and Melinda Gates Foundation, via International Initiative for Impact Evaluation (3ie)

Replication Study of Male Circumcision to Prevent HIV

The goal of this project was to evaluate and replicate the results of a randomized controlled trial of male circumcision for the reduction of HIV incidence, performed in Kisumu, Kenya (Bailey 2007).

5 U10 DA013727-15S1 (Brady) 09/15/14 – 08/31/15

NIH/NIDA

*“Southern Consortium Node of the Clinical Trials Network – Administrative Supplement”*

Dr. Korte wrote this application for an administrative supplement, and led the project to conduct statistical analyses of pooled data from completed studies conducted in the NIDA/CTN, focusing on gender differences in the interrelationships between sexual abuse, risky sexual behavior, and anxiety/depression in treatment efficacy and drug use over time among individuals with substance use disorders.

Role: Co-investigator